Key facts
- It has raised $434.2M across 2 recorded rounds; the latest was Later Stage VC (Series D) ($299.2M) in Jan 2019.
- 4 institutional filers report fund marks on BridgeBio Pharma across 25 filings.
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for BridgeBio Pharma
Create free account
No card required
Funding rounds
2 roundsJan 2019Later Stage VC (Series D)$299.2M▮
Apr 2018Later Stage VC (Series C)$135.0M▮
About BridgeBio Pharma
- Industry
- Pharmaceuticals
PA Mark — not yet priced
BridgeBio Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in BridgeBio Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
4 filers · latest May 20264 SEC-registered funds reported 25 fair-value marks on BridgeBio Pharma between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.